An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA)

Roche

Status: Completed

Conditions: Renal Cell Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01392729

ML25255

Details and patient eligibility

About

This prospective observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in combination with interferon alpha 2a in patients with previously untreated metastatic renal cell cancer. Data will be collected from each patient for up to 4 years.

Enrollment: 40 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/= 18 years of age
• Histologically confirmed metastatic renal cell cancer, clear cell type
• Eligible for treatment with Avastin and interferon alpha 2a according to local prescribing information

Exclusion criteria

• Contraindications for Avastin or interferon alpha 2a treatment according to local Summary of Product Characteristics
• Known hypersensitivity to Avastin and/or interferon alpha 2a or any of its excipients

Trial design

40 participants in 1 patient group

Cohort